Search results
21 hours ago · Johnson & Johnson today announced new data from the Phase 3 MARIPOSA study demonstrating the benefit of first-line treatment with RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in ...
54 minutes ago · RYBREVANT ® can cause infusion-related ... 1-2, 2.2% were Grade 3, and 0.4% were Grade 4. The median time to onset was 1 hour (range 0.1 to 18 hours) after start of infusion. ... accident, cardio ...
21 hours ago · The median time to onset was 1 hour (range 0.1 to 18 hours) after start of infusion. The incidence of infusion modifications due to IRR was 62%, and 1.3% of patients permanently discontinued ...
21 hours ago · "These new data demonstrate the efficacy of RYBREVANT plus lazertinib, showing a significant reduction in the risk of disease progression or death compared to osimertinib in several high-risk subgroups of patients with EGFR-mutated NSCLC," said Byoung Chul Cho , M.D., Ph.D., medical oncologist and professor in the Division of Medical Oncology at Yonsei Cancer Center, Yonsei University College ...
1 hour ago · Matt Szabo is a sports reporter for the Daily Pilot. A Southern California native and Cal Poly San Luis Obispo graduate, he has been covering sports for L.A. Times Community News since 2006, most ...
21 hours ago · Lund, Sweden, 31 May, 2024. Hansa Biopharma AB, , today announced recruitment and randomization in its US ConfIdeS trial is complete. ConfIdeS is a pivotal Phase 3 open label, randomized, controlled...
21 hours ago · The wolf ( Canis lupus; [b] pl.: wolves ), also known as the gray wolf or grey wolf, is a large canine native to Eurasia and North America. More than thirty subspecies of Canis lupus have been recognized, including the dog and dingo, though gray wolves, as popularly understood, only comprise naturally-occurring wild subspecies.
